The class action law suits keep piling up against Pozen after its proposed migraine drugs ran into problems with the FDA.

Eleven firms have sued Pozen.

The Washington firm of Cohen, Milstein, Hausfeld & Toll filed suit on Wednesday, charging that Pozen and “certain of its officers and directors” issued “a series of false and misleading statements regarding the migraine drugs MT-100 and MT-300.”

The first suit was filed on June 4.

Pozen (Nasdaq: POZN) closed at $6.71 on Wednesday, up 11 cents. It’s 52-week high is $19.40 — before the migraine drugs ran into turbulence.